tDCS for the treatment of negative symptoms in youth at clinical-high-risk for psychosis: A feasibility study.

Journal

Psychiatry research. Neuroimaging
ISSN: 1872-7506
Titre abrégé: Psychiatry Res Neuroimaging
Pays: Netherlands
ID NLM: 101723001

Informations de publication

Date de publication:
30 Aug 2024
Historique:
received: 01 09 2023
revised: 06 08 2024
accepted: 21 08 2024
medline: 1 9 2024
pubmed: 1 9 2024
entrez: 1 9 2024
Statut: aheadofprint

Résumé

Negative symptoms are often found in youth at clinical high risk (CHR) for psychosis. The present study explored the feasibility of using tDCS in conjunction with CBT in the treatment of negative symptoms in 5 youths at CHR. We sought to determine whether the protocol was feasible given the requirement for repeated visits over a three-week period, and to determine if measures of neurobiological change could be included, both acutely and following three weeks of stimulation. The results from this study suggest that the protocol is feasible for these youth, and the inclusion of MRI scanning sessions yielded good quality data.

Identifiants

DOI: 10.1016/j.pscychresns.2024.111879 PMID: 39217671
pubmed: 39217671
pii: S0925-4927(24)00102-1
doi: 10.1016/j.pscychresns.2024.111879
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

111879

Informations de copyright

Copyright © 2024 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest P.D.M., M.M.D., K.B., S.B., F.M., A.H., and J.A. have nothing to declare. A.M. is founder and shareholder of MCGRx Corp.

Auteurs

Paul D Metzak (PD)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta Canada; NonInvasive Neurostimulation Network (N3), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Electronic address: paul.metzak@ucalgary.ca.

Marilena M DeMayo (MM)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta Canada; Department of Radiology, University of Calgary, Calgary, Alberta Canada; NonInvasive Neurostimulation Network (N3), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada.

Kali Brummitt (K)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta Canada.

Signe Bray (S)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta Canada; Department of Radiology, University of Calgary, Calgary, Alberta Canada; NonInvasive Neurostimulation Network (N3), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada; Child & Adolescent Imaging Research (CAIR) Program, Calgary, Alberta, Canada.

Frank MacMaster (F)

Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia, Canada; IWK Health, Halifax, Nova Scotia, Canada.

Ashley Harris (A)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta Canada; Department of Radiology, University of Calgary, Calgary, Alberta Canada; NonInvasive Neurostimulation Network (N3), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada; Child & Adolescent Imaging Research (CAIR) Program, Calgary, Alberta, Canada.

Alexander McGirr (A)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta Canada; NonInvasive Neurostimulation Network (N3), Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

Jean Addington (J)

Hotchkiss Brain Institute, Department of Psychiatry, University of Calgary, Calgary, Alberta Canada.

Classifications MeSH